TRADING UPDATES: Zenith Energy in Rome buy; Concurrent revenue rises
The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Zenith Energy Ltd - energy production and development company with assets in Italy, US and Tunisia - Zenith acquires a photovoltaic development project in Rome, taking its development pipeline to 193 megawatt peaks. The total land consideration is EUR315,000. "Consideration is payable only upon securing all required permits and achieving ready-to-build status, in line with the company's capital-efficient acquisition model," Zenith adds.
----------
Concurrent Technologies PLC - Colchester, England-based designer and manufacturer of computer products for use in critical embedded applications - Concurrent expects "record" first half results, with order intake up more than double. It expects revenue for the six months to June 30 of £23.1 million, up from £21.1 million, with pretax profit climbing to £3.3 million from £2.7 million. Order intake surges to £46.9 million from £22.3 million, helped by a £17 million multi-year order secured from a European customer. "Excluding this order, the group nevertheless achieved record order intake compared to any prior half-year period," it adds. It says it is "well-positioned" to meet consensus of £8 million pretax profit and £53 million revenue for the whole of 2026. In 2025, it reported pretax profit of £6.5 million, on revenue of £45.9 million.
----------
Sabien Technology Group PLC - London-based provider of energy reduction technologies - Revenue for the year to June 30 is expected to have declined to around £746,000 from £846,015. Customer orders received during the year decline to around £908,000 from £948,053. "The company enters FY2027 with confirmed customer orders of over £196,000, compared with £59,453 at the beginning of FY2026, providing materially improved revenue visibility entering the new financial year," Sabien adds. In May, it launched a strategic review, which "included discussions regarding potential strategic investment and commercial partnership opportunities". "Those discussions remain ongoing. No agreement has been reached and there can be no certainty that any transaction will ultimately proceed. The board is evaluating alternative structures and will only pursue a transaction where it believes the commercial terms appropriately reflect the long-term strategic value of the company, maintain an appropriate balance of commercial risk and reward, and are demonstrably in the best interests of all shareholders," Sabien adds.
----------
Genedrive PLC - Manchester, England-based point-of-care pharmacogenetic testing company - Genedrive hails "significant commercial and operational progress" in the year to June 30. It expects to report revenue rose to £1.4 million from £1.0 million, in line with board expectations. "The board remains encouraged by increasing clinical adoption of both the Genedrive CYP2C19 and MT-RNR1 ID Kits, the growing evidence base supporting point-of-care pharmacogenetic testing, and the continued progress towards wider NHS implementation. The commercial and operational progress achieved during FY26 reinforces the board's confidence in the long-term opportunity for both products," Genedrive says.
----------
Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm focused on cancer immunotherapy - Poolbeg reports the first patient has been dosed in the POLB 001 clinical trial, which is testing the therapy as a preventative approach to cytokine release syndrome in some sufferers of blood cancer myeloma. The patients are receiving antibody teclistamab, which has been supplied by Johnson & Johnson at "no cost". Cytokine release syndrome is an inflammation. Poolbeg Chief Executive Officer Jeremy Skillington said: "The dosing of the first patient is an important milestone as we evaluate POLB 001 as a potential therapy to prevent CRS associated with cancer immunotherapies. Bispecific antibodies, such as teclistamab, are rapidly improving cancer patient outcomes and are increasingly being used earlier in disease treatment, making effective CRS management a priority for patients, clinicians and healthcare systems."
----------
Aptamer Group PLC - York, England-based synthetic binders developer - It expects revenue of £1.5 million for the year to June 30, growth of 25%. Aptamer's sales pipeline is up 55% at £4.8 million, with its order book for financial 2027 of around £600,000. "The broader £4.8 million sales pipeline includes later-stage discussions and early-stage licensing opportunities that are expected to convert over multiple periods," Aptamer adds.
----------
First Development Resources PLC - explorer for critical minerals and rare-earth elements in Western Australia and Northern Territory - Begins phase one reverse circulation drilling at the Lander West gold target within the Selta project. Selta is situated in the Northern Territory. "The phase I programme has been designed to test multiple high-priority gold targets generated through the company's systematic exploration programme, including geological mapping, geochemistry, airborne magnetics, gradient array induced polarisation geophysics and target generation," the firm says. "The programme is expected to comprise up to approximately 3,000 metres of RC drilling and will be completed in stages, allowing geological observations from the initial holes to inform subsequent targeting."
----------
80 Mile PLC - portfolio of energy, critical minerals and industrial gas projects with assets in Greenland, Finland and Italy - Drilling is now underway at the Disko-Nuussuaq nickel-copper-cobalt-PGE project in Greenland. "Each hole is planned to reach a maximum depth of 1,000 metres, subject to ongoing rig-site assessment and geological review," 80 Mile says.
----------
Nativo Resources PLC - exploration company with interests in precious metals mining and production in Peru - Nativo revises its phased development plan at the La Patona gold ore processing plant. "Following completion of front-end engineering design, detailed line-item capital costings and production modelling, the company has re-sequenced the development of La Patona into three phases, designed to optimise capital deployment, accelerate time to first revenue and reduce scale-up risk," Nativo explains. The first phase includes the crushing, milling and cyanidation circuit. The new capital expenditure estimate for this phase stands at USD2.0 million, USD2.8 million when including a 35% contingency. The prior estimate was USD1.8 million. The next phase is a cyanidation circuit capacity expansion, for a capex estimate of USD90,000. The last phase is the addition of a flotation circuit, at the cost of USD1.1 million. Project finance, royalty stream finance and equity finance will fund the first phase, but subsequent stages are funded through free cash flow from phase 1, "removing further capex requirements for scale-up". "Final investment decision remains subject only to completion of project financing; advanced financing discussions continue with multiple potential funding partners and the offtake proposal from a major commodities trading house remains under consideration," Nativo adds.
----------
Cobra Resources PLC - South Australian mineral exploration and development company - Cobra formally exercises its option to acquire the Manna Hill copper asset in South Australia. The firm reports "observations" from the latest four-hole drilling phase, which shows "high-grade intersections". Managing Director Rupert Verco says: "Whilst we wait for laboratory results, geological observations to date provide encouraging indicators of an extensive and fertile porphyry system. Diamond drilling provides a greater understanding of the structural and geological control and will enable us to refine drilling programmes to optimise outcomes. This drilling has extended observed sulphide mineralisation to a depth of 300m within a high-grade portion of the existing footprint." In August of last year, it announced a binding option deed on Manna Hill. At the time, it said the consideration for the option was AUD1.0 million, around £518,341, in company shares. Terms also included a reimbursement of the seller's substantiated project expenditure.
----------
ICFG Ltd - investment company established to acquire businesses focused on improving the delivery and use of financial services in Asia - A syndicated financing facility with arranger and administrative agent Helicap Securities Pte Ltd has been increased. The facility is now worth USD40 million, up from USD25 million. "The expanded facility will further strengthen the lending capacity of Pocket NBFI LLC and support the continued growth of the group's digital financial services platform in Mongolia. Pocket NBFI LLC operates Pocket, the group's proprietary fintech platform, which serves more than 900,000 registered customers and functions as a digital financial marketplace, connecting users with a range of financial service providers," ICFG says.
----------
Copyright 2026 Alliance News Ltd. All Rights Reserved.